person · Reporting owner

Topper James N

Disclosed activity across 16 companies

Tapewire entity: 26591
SEC CIK: 0001341382

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ANAPTYSBIO, INCANAB · Entity 4640	Director · 10% owner	January 06, 2023	January 11, 2023
Allena Pharmaceuticals, Inc.ALNA · Entity 130904	Director · 10% owner	November 17, 2020	November 18, 2020
Aptinyx Inc.APTX · Entity 120922	Director	March 31, 2020	April 02, 2020
Attovia Therapeutics, Inc.ATTO · Entity 4984	Director	August 04, 2026	August 04, 2026
Frazier Lifesciences Acquisition CorpFLAC · Entity 122080	Director · Chief Executive Officer	December 08, 2020	December 17, 2020
MBX Biosciences, Inc.MBX · Entity 4247	10% owner	September 26, 2025	September 30, 2025
Mirum Pharmaceuticals, Inc.MIRM · Entity 2416	10% owner	July 22, 2019	July 24, 2019
NewAmsterdam Pharma Co N.V.NAMS · Entity 1826	Director	September 15, 2025	September 17, 2025
Passage BIO, Inc.PASG · Entity 7829	10% owner	March 03, 2020	March 03, 2020
Phathom Pharmaceuticals, Inc.PHAT · Entity 5177	Director · 10% owner	May 19, 2026	May 21, 2026
Sierra Oncology, Inc.SRRA · Entity 125698	Director · 10% owner	February 14, 2017	February 16, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ANAPTYSBIO, INC

Report date January 06, 2023 · Filed January 11, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.23 · Expires 2033-01-05	Direct	10,600	Reported balance After 2023-01-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-01-06 · Grant · Acquired 10,600 · Balance 10,600 F1: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	3,900	Reported balance After 2023-01-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-01-06 · Grant · Acquired 3,900 · Balance 3,900 F2: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F2: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Allena Pharmaceuticals, Inc.

Report date November 17, 2020 · Filed November 18, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2030-11-16	Direct	14,000	Reported balance After 2020-11-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-11-17 · Grant · Acquired 14,000 · Balance 14,000 F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders.

Aptinyx Inc.

Report date March 31, 2020 · Filed April 02, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,195,055	Reported balance After 2020-03-31 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2020-03-31 · Grant · Acquired 4,976 · Balance 3,195,055 F1: The shares were issued to the Reporting Person, who elected to take unrestricted shares in lieu of cash compensation for services as a director, pursuant to the Issuer's nonemployee director compensation plan. The number of shares issued was determined by dividing the cash compensation otherwise payable with respect to the quarter by the price of a share on the date of the grant. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII"). FHM Life Sciences VIII, L.P. ("FHM-VIII L.P.") serves as the sole general partner of FLS-VIII and owns no shares directly. FHM Life Sciences VIII, LLC ("FHM-VIII LLC") serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. James N. Topper and Patrick Heron are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were issued to the Reporting Person, who elected to take unrestricted shares in lieu of cash compensation for services as a director, pursuant to the Issuer's nonemployee director compensation plan. The number of shares issued was determined by dividing the cash compensation otherwise payable with respect to the quarter by the price of a share on the date of the grant.

F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII"). FHM Life Sciences VIII, L.P. ("FHM-VIII L.P.") serves as the sole general partner of FLS-VIII and owns no shares directly. FHM Life Sciences VIII, LLC ("FHM-VIII LLC") serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. James N. Topper and Patrick Heron are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein.

Attovia Therapeutics, Inc.

Report date August 04, 2026 · Filed August 04, 2026

This filing explicitly reported no securities owned.

Frazier Lifesciences Acquisition Corp

Report date December 08, 2020 · Filed December 17, 2020 · Amendment

Jointly reported with Frazier Lifesciences Sponsor LLC, Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Heron Patrick J

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Ordinary SharesSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2020-12-08 · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · Balance Not disclosed F1: As described in the Issuer's Registration Statement on Form S-1 (File No. 333-250858) (the "Registration Statement") under the heading "Description of Securities," the Class B Ordinary Shares will automatically convert into Class A Ordinary Shares of the Issuer at the time of the Issuer's initial business combination and have no expiration date. The shares reported herein include up to 450,000 Class B Ordinary Shares that are subject to forfeiture if the underwriter of the Issuer's initial public offering does not exercise in full its option to purchase additional units, as described in the Registration Statement. F2: Frazier Lifesciences Sponsor LLC is the record holder of the shares reported herein. Frazier Life Sciences X, L.P. is the sole member of Frazier Lifesciences Sponsor LLC. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. Mr. Topper is the Chief Executive Officer and Chairman of the Board of Directors (the "Board") of the Issuer. F3: By virtue of Mr. Topper's representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons may be deemed directors by deputization of the Issuer. As such, each of Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Mr. Topper and Mr. Heron may be deemed to have or share beneficial ownership of the common stock held directly by Frazier Lifesciences Sponsor LLC. Each such entity or person disclaims any such beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the Issuer's Registration Statement on Form S-1 (File No. 333-250858) (the "Registration Statement") under the heading "Description of Securities," the Class B Ordinary Shares will automatically convert into Class A Ordinary Shares of the Issuer at the time of the Issuer's initial business combination and have no expiration date. The shares reported herein include up to 450,000 Class B Ordinary Shares that are subject to forfeiture if the underwriter of the Issuer's initial public offering does not exercise in full its option to purchase additional units, as described in the Registration Statement.

F2: Frazier Lifesciences Sponsor LLC is the record holder of the shares reported herein. Frazier Life Sciences X, L.P. is the sole member of Frazier Lifesciences Sponsor LLC. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. Mr. Topper is the Chief Executive Officer and Chairman of the Board of Directors (the "Board") of the Issuer.

F3: By virtue of Mr. Topper's representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons may be deemed directors by deputization of the Issuer. As such, each of Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Mr. Topper and Mr. Heron may be deemed to have or share beneficial ownership of the common stock held directly by Frazier Lifesciences Sponsor LLC. Each such entity or person disclaims any such beneficial ownership of such securities except to the extent of their pecuniary interest therein.

MBX Biosciences, Inc.

Report date September 26, 2025 · Filed September 30, 2025

Jointly reported with Heron Patrick J, FHMLS X, L.P., FHMLS X, L.L.C., Frazier Life Sciences X, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Frazier Life Sciences X, L.P.	5,219,440	Reported balance After 2025-09-26 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-09-26 · Purchase · Acquired 666,666 · Balance 5,219,440 F1: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Mirum Pharmaceuticals, Inc.

Report date July 22, 2019 · Filed July 24, 2019

Jointly reported with Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,566,912	Last balance in matching sequence After 2019-07-22 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2019-07-22 · Conversion · Acquired 3,116,912 · Balance 3,116,912 F1: In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any. Row 2 · 2019-07-22 · Purchase · Acquired 450,000 · Balance 3,566,912 F3: The shares were purchased in the Issuer's initial public offering. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-07-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-07-22 · Conversion · Disposed 24,935,300 · Balance 0 F1: In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date.

F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.

F3: The shares were purchased in the Issuer's initial public offering.

NewAmsterdam Pharma Co N.V.

Report date September 15, 2025 · Filed September 17, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	IndirectBy Frazier Life Sciences X, L.P.	3,028,524	Reported balance After 2025-09-15 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-09-15 · Purchase · Acquired 660 · Balance 3,028,524 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.46 to $23.75. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F2: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Frazier Lifesciences Sponsor LLC	3,801,000	Reported balance Holding disclosure · report date 2025-09-15 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,801,000 F3: The shares are held directly by Frazier Lifesciences Sponsor LLC. The sole member of Frazier Lifesciences Sponsor LLC is Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.46 to $23.75. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.

F2: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F3: The shares are held directly by Frazier Lifesciences Sponsor LLC. The sole member of Frazier Lifesciences Sponsor LLC is Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Passage BIO, Inc.

Report date March 03, 2020 · Filed March 03, 2020

Jointly reported with Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,009,219	Last balance in matching sequence After 2020-03-03 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2020-03-03 · Conversion · Acquired 2,977,242 · Balance 2,977,242 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any. Row 2 · 2020-03-03 · Conversion · Acquired 1,049,175 · Balance 4,026,417 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any. Row 3 · 2020-03-03 · Conversion · Acquired 432,802 · Balance 4,459,219 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any. Row 4 · 2020-03-03 · Purchase · Acquired 550,000 · Balance 5,009,219 F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-03-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-03-03 · Conversion · Disposed 2,977,242 · Balance 0 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.
Series A-2 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-03-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-03-03 · Conversion · Disposed 1,049,175 · Balance 0 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-03-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-03-03 · Conversion · Disposed 432,802 · Balance 0 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020.

F2: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.

Phathom Pharmaceuticals, Inc.

Report date May 19, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	66,718	Reported balance After 2026-05-19 transaction · row 1 1 source row Row 1 · 2026-05-19 · Grant · Acquired 24,122 · Balance 66,718 F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Common StockSEC Table I · non-derivative	IndirectBy Frazier Life Sciences X, L.P.	59,403	Reported balance Holding disclosure · report date 2026-05-19 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 59,403 F2: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Frazier Life Sciences IX, L.P.	5,827,415	Reported balance Holding disclosure · report date 2026-05-19 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 5,827,415 F3: The shares reported herein are held of record by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. and FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy FHMLS IX, L.L.C.	1	Reported balance Holding disclosure · report date 2026-05-19 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 1 F4: The shares reported herein are held of record by FHMLS IX, L.L.C. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Topper Group III LLC	3,912	Reported balance Holding disclosure · report date 2026-05-19 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 3,912 F5: The Reporting Person is a manager of Topper Group III LLC and has voting and investment power of the securities held by Topper Group III LLC.

Filing footnotes · ownership attribution and instrument terms

F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F3: The shares reported herein are held of record by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. and FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F4: The shares reported herein are held of record by FHMLS IX, L.L.C. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F5: The Reporting Person is a manager of Topper Group III LLC and has voting and investment power of the securities held by Topper Group III LLC.

Sierra Oncology, Inc.

Report date February 14, 2017 · Filed February 16, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Frazier Life Sciences VIII, L.P.	5,925,926	Reported balance After 2017-02-14 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2017-02-14 · Purchase · Acquired 5,925,926 · Balance 5,925,926 F1: The reporting person and Patrick Heron are the managing members of FHM Life Sciences VIII, L.L.C., which is the general partner of FHM Life Sciences VIII, L.P., which is the general partner of Frazier Life Sciences VIII, L.P. ("FLSIII"), the record holder of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by FLSIII. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Common StockSEC Table I · non-derivative	IndirectBy Frazier Healthcare VI, L.P.	2,186,195	Reported balance Holding disclosure · report date 2017-02-14 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 2,186,195 F2: The reporting person, Alan Frazier, Nader Naini, Nathan Every and Patrick Heron are the managing members of FHM VI, LLC, which is the general partner of FHM VI, LP, which is the general partner of Frazier Healthcare VI, L.P. ("FHVI"), the record holder of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by FHVI. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person and Patrick Heron are the managing members of FHM Life Sciences VIII, L.L.C., which is the general partner of FHM Life Sciences VIII, L.P., which is the general partner of Frazier Life Sciences VIII, L.P. ("FLSIII"), the record holder of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by FLSIII. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

F2: The reporting person, Alan Frazier, Nader Naini, Nathan Every and Patrick Heron are the managing members of FHM VI, LLC, which is the general partner of FHM VI, LP, which is the general partner of Frazier Healthcare VI, L.P. ("FHVI"), the record holder of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by FHVI. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALPINE IMMUNE SCIENCES, INC.

Report date May 18, 2024 · Filed May 21, 2024

Section 16 reporting ended · disclosed 2024-05-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Frazier Life Sciences VIII, L.P.	Reported balance After 2024-05-18 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-05-18 · Other · Disposed 2,829,347 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F3: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.31 · Expires 2028-01-01	Direct	Reported balance After 2024-05-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2029-01-01	Direct	Reported balance After 2024-05-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2030-01-01	Direct	Reported balance After 2024-05-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.45 · Expires 2031-01-03	Direct	Reported balance After 2024-05-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.89 · Expires 2032-01-02	Direct	Reported balance After 2024-05-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-05-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2033-01-02	Direct	Reported balance After 2024-05-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-05-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2034-01-01	Direct	Reported balance After 2024-05-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-05-20 · Disposition to issuer · Disposed 17,500 · Balance 0 F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

F2: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.

F3: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any.

F4: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F5: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.

F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.

F7: (Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.

F8: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter.

Arcutis Biotherapeutics, Inc.

Report date October 24, 2023 · Filed October 26, 2023

Jointly reported with Frazier Life Sciences VIII, L.P., FHM LIFE SCIENCES VIII, L.P., FHM LIFE SCIENCES VIII, L.L.C., Heron Patrick J

Section 16 reporting ended · disclosed 2023-10-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,764,232	Reported balance After 2023-10-24 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-10-24 · Purchase · Acquired 80,000 · Balance 8,764,232
Common StockSEC Table I · non-derivative	IndirectFHM Life Sciences VIII, L.L.C.	7	Reported balance Holding disclosure · report date 2023-10-24 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 7 F1: Represents shares held of record by FHM Life Sciences VIII, L.L.C. Dr. Topper and Mr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.L.C. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Topper Group II LLC	11,266	Reported balance Holding disclosure · report date 2023-10-24 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 11,266 F2: Dr. Topper is a manager of Topper Group II LLC and shares voting and investment power over the shares held by Topper Group II LLC.
Common StockSEC Table I · non-derivative	IndirectBy Topper Family Revocable Trust	19,381	Reported balance Holding disclosure · report date 2023-10-24 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 19,381 F3: Dr. Topper is a trustee of the Topper Family Revocable Trust and has voting and investment power over the shares held by Topper Family Revocable Trust.
Common StockSEC Table I · non-derivative	IndirectBy The Heron Living Trust 11/30/2004	23,688	Reported balance Holding disclosure · report date 2023-10-24 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 23,688 F4: Mr. Heron is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004.
Common StockSEC Table I · non-derivative	IndirectBy Patrick J. Heron	8,687	Reported balance Holding disclosure · report date 2023-10-24 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 8,687 F5: Includes 4,375 Restricted Stock Units ("RSUs"). Mr. Heron is entitled to receive one (1) share of the Issuer's Common Stock for each one (1) RSU upon the vesting thereof.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares held of record by FHM Life Sciences VIII, L.L.C. Dr. Topper and Mr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.L.C. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F2: Dr. Topper is a manager of Topper Group II LLC and shares voting and investment power over the shares held by Topper Group II LLC.

F3: Dr. Topper is a trustee of the Topper Family Revocable Trust and has voting and investment power over the shares held by Topper Family Revocable Trust.

F4: Mr. Heron is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004.

F5: Includes 4,375 Restricted Stock Units ("RSUs"). Mr. Heron is entitled to receive one (1) share of the Issuer's Common Stock for each one (1) RSU upon the vesting thereof.

Entasis Therapeutics Holdings Inc.

Report date January 09, 2020 · Filed January 13, 2020

Jointly reported with Frazier Life Sciences VIII, L.P., FHM LIFE SCIENCES VIII, L.P., FHM LIFE SCIENCES VIII, L.L.C., Heron Patrick J

Section 16 reporting ended · disclosed 2020-01-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,299,953	Reported balance After 2020-01-09 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-01-09 · Sale · Disposed 50,000 · Balance 1,299,953 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4 F2: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4

F2: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any.

HilleVax, Inc.

Report date September 17, 2025 · Filed September 17, 2025

Jointly reported with Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Heron Patrick J

Section 16 reporting ended · disclosed 2025-09-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Frazier Life Sciences X, L.P.	0	Reported balance After 2025-09-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-09-17 · Other · Disposed 8,535,337 · Balance 0 F1: Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on September 17, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares"), issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive (i) $1.95 in cash, without interest plus (ii) one non-transferable contractual contingent value right per Share. F2: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Patrick J. Heron	0	Reported balance After 2025-09-17 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-09-17 · Other · Disposed 17,199 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the $1.95 by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on September 17, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares"), issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive (i) $1.95 in cash, without interest plus (ii) one non-transferable contractual contingent value right per Share.

F2: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the $1.95 by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.

Tarsus Pharmaceuticals, Inc.

Report date October 20, 2020 · Filed October 21, 2020

Jointly reported with Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C., Heron Patrick J

Section 16 reporting ended · disclosed 2020-10-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,917,157	Last balance in matching sequence After 2020-10-20 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2020-10-20 · Conversion · Acquired 1,390,376 · Balance 1,390,376 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein. Row 2 · 2020-10-20 · Conversion · Acquired 214,281 · Balance 1,604,657 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein. Row 3 · 2020-10-20 · Purchase · Acquired 312,500 · Balance 1,917,157 F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-10-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-20 · Conversion · Disposed 1,390,376 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-10-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-20 · Conversion · Disposed 214,281 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 29, 2019 Filed Oct 30, 2019 17:04 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	PurchaseCommon Stock	1,052,631	$19.00	$19,999,989.00	Disclosure SEC source: 0001209191-19-054525 · doc4.xml · nonDerivative · entry 2 Frazier Life Sciences IX, L.P. · CIK 0001720320 · 10% owner Topper James N · CIK 0001341382 · Director · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner FHMLS IX, L.L.C. · CIK 0001782791 · 10% owner FHMLS IX, L.P. · CIK 0001782789 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,284,269 F2 · ownership.direct: The shares reported herein are held of record by Frazier Life Sciences IX, L.P. ("FLS IX"). The general partner of FLS IX is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
October 29, 2019 Filed Oct 30, 2019 17:04 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	ConversionCommon Stock	1,353,640	$15.20	$20,575,328.00	Disclosure SEC source: 0001209191-19-054525 · doc4.xml · nonDerivative · entry 1 Frazier Life Sciences IX, L.P. · CIK 0001720320 · 10% owner Topper James N · CIK 0001341382 · Director · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner FHMLS IX, L.L.C. · CIK 0001782791 · 10% owner FHMLS IX, L.P. · CIK 0001782789 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,231,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, the outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock based on a conversion price of $15.20 per share. F2 · ownership.direct: The shares reported herein are held of record by Frazier Life Sciences IX, L.P. ("FLS IX"). The general partner of FLS IX is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
September 30, 2019 Filed Oct 2, 2019 16:17 UTC	Aptinyx Inc. APTX · Entity 120922	GrantStock Option (Right to Buy) · Derivative	5,162	$2.08 Strike: $3.49	$10,747.28	Disclosure SEC source: 0001567619-19-019067 · doc1.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,162 Underlying: Common Stock · 5,162 shares Expires 2029-09-29 F1 · shares: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document
July 22, 2019 Filed Jul 24, 2019 16:17 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	ConversionSeries A Preferred Stock · Derivative	24,935,300	$0.00	$0.00	Disclosure SEC source: 0001209191-19-043024 · doc4.xml · derivative · entry 3 Frazier Life Sciences IX, L.P. · CIK 0001720320 · 10% owner FHMLS IX, L.P. · CIK 0001782789 · 10% owner FHMLS IX, L.L.C. · CIK 0001782791 · 10% owner Topper James N · CIK 0001341382 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,116,912 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date. F1 · derivative.exercise_date: In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date. F1 · derivative.expiration_date: In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date. F1 · derivative.underlying_shares: In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date. F2 · ownership.direct: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any. Read SEC document
July 22, 2019 Filed Jul 24, 2019 16:17 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	PurchaseCommon Stock	450,000	$15.00	$6,750,000.00	Disclosure SEC source: 0001209191-19-043024 · doc4.xml · nonDerivative · entry 2 Frazier Life Sciences IX, L.P. · CIK 0001720320 · 10% owner FHMLS IX, L.P. · CIK 0001782789 · 10% owner FHMLS IX, L.L.C. · CIK 0001782791 · 10% owner Topper James N · CIK 0001341382 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,566,912 F3 · kind: The shares were purchased in the Issuer's initial public offering. F2 · ownership.direct: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any. Read SEC document
July 22, 2019 Filed Jul 24, 2019 16:17 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	ConversionCommon Stock	3,116,912	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-043024 · doc4.xml · nonDerivative · entry 1 Frazier Life Sciences IX, L.P. · CIK 0001720320 · 10% owner FHMLS IX, L.P. · CIK 0001782789 · 10% owner FHMLS IX, L.L.C. · CIK 0001782791 · 10% owner Topper James N · CIK 0001341382 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,116,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date. F1 · price: In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date. F2 · ownership.direct: The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any. Read SEC document
June 28, 2019 Filed Jul 2, 2019 17:02 UTC	Aptinyx Inc. APTX · Entity 120922	GrantStock Option (Right to Buy) · Derivative	5,424	$1.98 Strike: $3.34	$10,750.37	Disclosure SEC source: 0001104659-19-039060 · a4.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,424 Underlying: Common Stock · 5,424 shares Expires 2029-06-27 F1 · shares: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document
June 05, 2019 Filed Jun 7, 2019 09:22 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	GrantStock Option (Right to Buy) · Derivative	14,000	$0.00 Strike: $5.59	$0.00	Disclosure SEC source: 0001209191-19-035403 · doc4.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-06-04 F1 · derivative.exercise_date: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders. Read SEC document
May 15, 2019 Filed May 17, 2019 17:00 UTC	Aptinyx Inc. APTX · Entity 120922	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $3.73	$0.00	Disclosure SEC source: 0001104659-19-030312 · a4.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-05-14 F1 · derivative.exercise_date: This option vests in ratable monthly installments over one year from the date of grant. Read SEC document
March 29, 2019 Filed Apr 2, 2019 16:25 UTC	Aptinyx Inc. APTX · Entity 120922	GrantStock Option (Right to Buy) · Derivative	4,433	$2.43 Strike: $4.05	$10,750.03	Disclosure SEC source: 0001104659-19-019385 · a4.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,433 Underlying: Common Stock · 4,433 shares Expires 2029-03-28 F1 · shares: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document
February 08, 2019 Filed Feb 11, 2019 22:39 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	GrantDirector Stock Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $68.89	$0.00	Disclosure SEC source: 0001209191-19-009044 · doc4.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-02-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 8, 2019, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document
January 18, 2019 Filed Jan 22, 2019 22:04 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $5.66	$0.00	Disclosure SEC source: 0001209191-19-004776 · doc4.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-01-17 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on January 1, 2020, subject to the Reporting Person continuing to provide service through such date. Read SEC document
January 18, 2019 Filed Jan 22, 2019 22:09 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	PurchaseWarrant (Right to Buy) · Derivative	145,251	$0.00 Strike: $12.74	$0.00	Disclosure SEC source: 0001209191-19-004779 · doc4.xml · derivative · entry 2 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Life Sciences VIII, L.P. Disclosed balance after: 145,251 Underlying: Common Stock · 145,251 shares Expires 2024-01-18 F1 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his pecuniary interest therein, if any. Read SEC document
January 18, 2019 Filed Jan 22, 2019 22:09 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	PurchaseCommon Stock	372,439	$5.37	$1,999,997.43	Disclosure SEC source: 0001209191-19-004779 · doc4.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Life Sciences VIII, L.P. Disclosed balance after: 2,571,450 F1 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his pecuniary interest therein, if any. Read SEC document
January 02, 2019 Filed Jan 4, 2019 21:02 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantStock Option (Right to buy) · Derivative	7,650	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0000899243-19-000503 · doc4.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,650 Underlying: Common Stock · 7,650 shares Expires 2029-01-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2019 and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document
September 28, 2018 Filed Oct 3, 2018 01:42 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	ConversionSeries B-1 Tranche B Convertible Preferred Stock · Derivative	6,651,574	$0.00	$0.00	Disclosure SEC source: 0001209191-18-053540 · doc4.xml · derivative · entry 7 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 320,898 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.underlying_shares: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. The Reporting Person, a director of the Issuer, is a managing member of FHM LLC. The Reporting Person disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his pecuniary interest in such shares. Read SEC document
September 28, 2018 Filed Oct 3, 2018 01:42 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	ConversionSeries B-1 Tranche A Convertible Preferred Stock · Derivative	5,212,833	$0.00	$0.00	Disclosure SEC source: 0001209191-18-053540 · doc4.xml · derivative · entry 6 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 251,487 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.underlying_shares: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. The Reporting Person, a director of the Issuer, is a managing member of FHM LLC. The Reporting Person disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his pecuniary interest in such shares. Read SEC document
September 28, 2018 Filed Oct 3, 2018 01:42 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	ConversionSeries B Convertible Preferred Stock · Derivative	7,000,000	$0.00	$0.00	Disclosure SEC source: 0001209191-18-053540 · doc4.xml · derivative · entry 5 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 337,707 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.underlying_shares: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. The Reporting Person, a director of the Issuer, is a managing member of FHM LLC. The Reporting Person disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his pecuniary interest in such shares. Read SEC document
September 28, 2018 Filed Oct 3, 2018 01:42 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	PurchaseCommon Stock	375,887	$15.00	$5,638,305.00	Disclosure SEC source: 0001209191-18-053540 · doc4.xml · nonDerivative · entry 4 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,349,953 F2 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. The Reporting Person, a director of the Issuer, is a managing member of FHM LLC. The Reporting Person disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his pecuniary interest in such shares. Read SEC document
September 28, 2018 Filed Oct 3, 2018 01:42 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	ConversionCommon Stock	320,898	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-053540 · doc4.xml · nonDerivative · entry 3 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 974,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · balance_after: This number includes an aggregate of 63,974 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018. F2 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. The Reporting Person, a director of the Issuer, is a managing member of FHM LLC. The Reporting Person disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his pecuniary interest in such shares. Read SEC document
September 28, 2018 Filed Oct 3, 2018 01:42 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	ConversionCommon Stock	251,487	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-053540 · doc4.xml · nonDerivative · entry 2 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 589,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. The Reporting Person, a director of the Issuer, is a managing member of FHM LLC. The Reporting Person disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his pecuniary interest in such shares. Read SEC document
September 28, 2018 Filed Oct 3, 2018 01:42 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	ConversionCommon Stock	337,707	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-053540 · doc4.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 337,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. The Reporting Person, a director of the Issuer, is a managing member of FHM LLC. The Reporting Person disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his pecuniary interest in such shares. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:54 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionSeries B Convertible Preferred Stock · Derivative	21,946,301	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042310 · a4.xml · derivative · entry 7 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 795,553 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII"). FHM Life Sciences VIII, L.P. ("FHM-VIII L.P.") serves as the sole general partner of FLS-VIII and owns no shares directly. FHM Life Sciences VIII, LLC ("FHM-VIII LLC") serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. James N. Topper and Patrick Heron are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:54 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionSeries A-2 Convertible Preferred Stock · Derivative	33,022,786	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042310 · a4.xml · derivative · entry 6 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,197,076 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII"). FHM Life Sciences VIII, L.P. ("FHM-VIII L.P.") serves as the sole general partner of FLS-VIII and owns no shares directly. FHM Life Sciences VIII, LLC ("FHM-VIII LLC") serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. James N. Topper and Patrick Heron are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:54 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionSeries A-1 Convertible Preferred Stock · Derivative	28,895,188	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042310 · a4.xml · derivative · entry 5 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,047,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII"). FHM Life Sciences VIII, L.P. ("FHM-VIII L.P.") serves as the sole general partner of FLS-VIII and owns no shares directly. FHM Life Sciences VIII, LLC ("FHM-VIII LLC") serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. James N. Topper and Patrick Heron are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:54 UTC	Aptinyx Inc. APTX · Entity 120922	PurchaseCommon Stock	150,000	$16.00	$2,400,000.00	Disclosure SEC source: 0001104659-18-042310 · a4.xml · nonDerivative · entry 4 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,190,079 F3 · shares: On June 25, 2018, FLS-VIII purchased 150,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII"). FHM Life Sciences VIII, L.P. ("FHM-VIII L.P.") serves as the sole general partner of FLS-VIII and owns no shares directly. FHM Life Sciences VIII, LLC ("FHM-VIII LLC") serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. James N. Topper and Patrick Heron are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:54 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionCommon Stock	795,553	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042310 · a4.xml · nonDerivative · entry 3 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,040,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII"). FHM Life Sciences VIII, L.P. ("FHM-VIII L.P.") serves as the sole general partner of FLS-VIII and owns no shares directly. FHM Life Sciences VIII, LLC ("FHM-VIII LLC") serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. James N. Topper and Patrick Heron are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:54 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionCommon Stock	1,197,076	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042310 · a4.xml · nonDerivative · entry 2 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,244,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII"). FHM Life Sciences VIII, L.P. ("FHM-VIII L.P.") serves as the sole general partner of FLS-VIII and owns no shares directly. FHM Life Sciences VIII, LLC ("FHM-VIII LLC") serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. James N. Topper and Patrick Heron are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:54 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionCommon Stock	1,047,450	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042310 · a4.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,047,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII"). FHM Life Sciences VIII, L.P. ("FHM-VIII L.P.") serves as the sole general partner of FLS-VIII and owns no shares directly. FHM Life Sciences VIII, LLC ("FHM-VIII LLC") serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. James N. Topper and Patrick Heron are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Read SEC document
June 08, 2018 Filed Jun 12, 2018 16:21 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	GrantStock Option (Right to Buy) · Derivative	10,182	$0.00 Strike: $13.52	$0.00	Disclosure SEC source: 0001209191-18-037232 · doc4.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,182 Underlying: Common Stock · 10,182 shares Expires 2028-06-07 F1 · derivative.exercise_date: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders. Read SEC document
May 11, 2018 Filed May 15, 2018 22:26 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	OtherCommon Stock	31,854	$0.00	$0.00	Disclosure SEC source: 0001012975-18-000438 · edgar.xml · nonDerivative · entry 4 Topper James N · CIK 0001341382 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,854 F4 · kind: Shares acquired by Dr. Topper through a distribution in-kind from FHM V, L.P. Read SEC document
May 11, 2018 Filed May 15, 2018 22:26 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	OtherCommon Stock	301,024	$0.00	$0.00	Disclosure SEC source: 0001012975-18-000438 · edgar.xml · nonDerivative · entry 3 Topper James N · CIK 0001341382 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F3 · kind: Effective May 11, 2018, FHM V, L.P. distributed in-kind, without consideration, a total of 301,024 shares of Common Stock of the Issuer to its limited partners. F3 · ownership.nature: Effective May 11, 2018, FHM V, L.P. distributed in-kind, without consideration, a total of 301,024 shares of Common Stock of the Issuer to its limited partners. Read SEC document
May 11, 2018 Filed May 15, 2018 22:26 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	OtherCommon Stock	301,024	$0.00	$0.00	Disclosure SEC source: 0001012975-18-000438 · edgar.xml · nonDerivative · entry 2 Topper James N · CIK 0001341382 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 301,024 F2 · kind: Shares acquired by FHM V, L.P. through a distribution in-kind from FH V. FHM V, L.L.C. is the general partner of FHM V, L.P. The reporting person disclaims beneficial ownership of all shares held by the foregoing entities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: Shares acquired by FHM V, L.P. through a distribution in-kind from FH V. FHM V, L.L.C. is the general partner of FHM V, L.P. The reporting person disclaims beneficial ownership of all shares held by the foregoing entities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 11, 2018 Filed May 15, 2018 22:26 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	OtherCommon Stock	1,372,000	$0.00	$0.00	Disclosure SEC source: 0001012975-18-000438 · edgar.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 973,612 F1 · kind: Effective May 11, 2018, Frazier Healthcare V, L.P. ("FH V"), distributed in-kind, without consideration, a total of 1,372,000 shares of Common Stock of the Issuer to its general and limited partners. The remaining securities are held by FH V. FHM V, L.L.C. is the general partner of FHM V, L.P. which is the general partner of FH V. The reporting person disclaims beneficial ownership of all shares held by the foregoing entities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: Effective May 11, 2018, Frazier Healthcare V, L.P. ("FH V"), distributed in-kind, without consideration, a total of 1,372,000 shares of Common Stock of the Issuer to its general and limited partners. The remaining securities are held by FH V. FHM V, L.L.C. is the general partner of FHM V, L.P. which is the general partner of FH V. The reporting person disclaims beneficial ownership of all shares held by the foregoing entities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
February 02, 2018 Filed Feb 6, 2018 21:20 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	GrantDirector Stock Option (right to buy) · Derivative	6,000	$0.00 Strike: $104.81	$0.00	Disclosure SEC source: 0001209191-18-007838 · doc4.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-02-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document
January 02, 2018 Filed Jan 4, 2018 22:38 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantStock Option (Right to buy) · Derivative	7,650	$0.00 Strike: $11.31	$0.00	Disclosure SEC source: 0000899243-18-000503 · doc4.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,650 Underlying: Common Stock · 7,650 shares Expires 2028-01-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 100% of the shares subject to the option become vested and exercisable on January 2, 2019. Read SEC document
November 06, 2017 Filed Nov 6, 2017 19:06 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	ConversionSeries C Preferred Stock · Derivative	1,061,904	$0.00	$0.00	Disclosure SEC source: 0000899243-17-025455 · doc4.xml · derivative · entry 7 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 254,409 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.174-for-1 basis upon closing of the initial public offering of the Issuer and have no expiration date. F2 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.174-for-1 basis upon closing of the initial public offering of the Issuer and have no expiration date. F2 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.174-for-1 basis upon closing of the initial public offering of the Issuer and have no expiration date. F3 · ownership.nature: These shares are held directly by Frazier Healthcare VI, L.P. The general partner of Frazier Healthcare VI, L.P is FHM VI, L.P., a Delaware limited partnership. The general partner of FHM VI, L.P. is FHM VI, L.L.C., a Delaware limited liability company. The Reporting Person is one of five members of FHM VI, L.L.C. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest in such shares, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
November 06, 2017 Filed Nov 6, 2017 19:06 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	ConversionSeries B Preferred Stock · Derivative	4,629,630	$0.00	$0.00	Disclosure SEC source: 0000899243-17-025455 · doc4.xml · derivative · entry 6 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,109,159 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.174-for-1 basis upon closing of the initial public offering of the Issuer and have no expiration date. F2 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.174-for-1 basis upon closing of the initial public offering of the Issuer and have no expiration date. F2 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.174-for-1 basis upon closing of the initial public offering of the Issuer and have no expiration date. F3 · ownership.nature: These shares are held directly by Frazier Healthcare VI, L.P. The general partner of Frazier Healthcare VI, L.P is FHM VI, L.P., a Delaware limited partnership. The general partner of FHM VI, L.P. is FHM VI, L.L.C., a Delaware limited liability company. The Reporting Person is one of five members of FHM VI, L.L.C. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest in such shares, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
November 06, 2017 Filed Nov 6, 2017 19:06 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	ConversionSeries A Preferred Stock · Derivative	6,122,448	$0.00	$0.00	Disclosure SEC source: 0000899243-17-025455 · doc4.xml · derivative · entry 5 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,466,805 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.174-for-1 basis upon closing of the initial public offering of the Issuer and have no expiration date. F2 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.174-for-1 basis upon closing of the initial public offering of the Issuer and have no expiration date. F2 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.174-for-1 basis upon closing of the initial public offering of the Issuer and have no expiration date. F3 · ownership.nature: These shares are held directly by Frazier Healthcare VI, L.P. The general partner of Frazier Healthcare VI, L.P is FHM VI, L.P., a Delaware limited partnership. The general partner of FHM VI, L.P. is FHM VI, L.L.C., a Delaware limited liability company. The Reporting Person is one of five members of FHM VI, L.L.C. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest in such shares, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
November 06, 2017 Filed Nov 6, 2017 19:06 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	PurchaseCommon Stock	500,000	$14.00	$7,000,000.00	Disclosure SEC source: 0000899243-17-025455 · doc4.xml · nonDerivative · entry 4 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,330,373 F3 · ownership.nature: These shares are held directly by Frazier Healthcare VI, L.P. The general partner of Frazier Healthcare VI, L.P is FHM VI, L.P., a Delaware limited partnership. The general partner of FHM VI, L.P. is FHM VI, L.L.C., a Delaware limited liability company. The Reporting Person is one of five members of FHM VI, L.L.C. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest in such shares, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
November 06, 2017 Filed Nov 6, 2017 19:06 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	ConversionCommon Stock	254,409	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-025455 · doc4.xml · nonDerivative · entry 3 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,830,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the total number of shares of Common Stock received by Frazier Healthcare VI, L.P. ("Frazier"), upon conversion of the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.174-for-1 basis upon closing of the initial public offering of the Issuer and have no expiration date. F3 · ownership.nature: These shares are held directly by Frazier Healthcare VI, L.P. The general partner of Frazier Healthcare VI, L.P is FHM VI, L.P., a Delaware limited partnership. The general partner of FHM VI, L.P. is FHM VI, L.L.C., a Delaware limited liability company. The Reporting Person is one of five members of FHM VI, L.L.C. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest in such shares, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
November 06, 2017 Filed Nov 6, 2017 19:06 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	ConversionCommon Stock	1,109,159	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-025455 · doc4.xml · nonDerivative · entry 2 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,575,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the total number of shares of Common Stock received by Frazier Healthcare VI, L.P. ("Frazier"), upon conversion of the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.174-for-1 basis upon closing of the initial public offering of the Issuer and have no expiration date. F3 · ownership.nature: These shares are held directly by Frazier Healthcare VI, L.P. The general partner of Frazier Healthcare VI, L.P is FHM VI, L.P., a Delaware limited partnership. The general partner of FHM VI, L.P. is FHM VI, L.L.C., a Delaware limited liability company. The Reporting Person is one of five members of FHM VI, L.L.C. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest in such shares, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
November 06, 2017 Filed Nov 6, 2017 19:06 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	ConversionCommon Stock	1,466,805	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-025455 · doc4.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,466,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the total number of shares of Common Stock received by Frazier Healthcare VI, L.P. ("Frazier"), upon conversion of the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.174-for-1 basis upon closing of the initial public offering of the Issuer and have no expiration date. F3 · ownership.nature: These shares are held directly by Frazier Healthcare VI, L.P. The general partner of Frazier Healthcare VI, L.P is FHM VI, L.P., a Delaware limited partnership. The general partner of FHM VI, L.P. is FHM VI, L.L.C., a Delaware limited liability company. The Reporting Person is one of five members of FHM VI, L.L.C. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest in such shares, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
July 24, 2017 Filed Jul 26, 2017 21:11 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantCommon Stock	2,199,011	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-019066 · doc4.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,199,011 F1 · shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F1 · price: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F2 · ownership.nature: The Reporting Person and Patrick Heron are the managing members of FHM Life Sciences VIII, L.L.C., which is the general partner of FHM Life Sciences VIII, L.P., which is the general partner of Frazier Life Sciences VIII, L.P. ("FLS VIII"), the record holder of the securities, and the Reporting Person may be deemed to share voting and dispositive power over the securities held by FLS VIII. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document
February 24, 2017 Filed Feb 28, 2017 23:46 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	GrantDirector Stock Option (right to buy) · Derivative	15,000	$0.00 Strike: $24.60	$0.00	Disclosure SEC source: 0001209191-17-015450 · doc4.xml · derivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-02-23 F1 · derivative.exercise_date: The stock option vests and becomes fully exercisable on February 24, 2018. Read SEC document
February 14, 2017 Filed Feb 16, 2017 17:11 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	PurchaseCommon Stock	5,925,926	$1.35	$8,000,000.10	Disclosure SEC source: 0001209191-17-011565 · doc4.xml · nonDerivative · entry 1 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Life Sciences VIII, L.P. Disclosed balance after: 5,925,926 F1 · ownership.nature: The reporting person and Patrick Heron are the managing members of FHM Life Sciences VIII, L.L.C., which is the general partner of FHM Life Sciences VIII, L.P., which is the general partner of Frazier Life Sciences VIII, L.P. ("FLSIII"), the record holder of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by FLSIII. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document
January 31, 2017 Filed Jan 31, 2017 21:51 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	ConversionSeries D Preferred Stock · Derivative	209,095	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-17-006406 · doc4.xml · derivative · entry 10 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 0 Underlying: Common Stock · 209,095 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F4 · ownership.nature: Represents shares held by Frazier Healthcare VII-A, L.P., an affiliate of Frazier Healthcare Ventures. Dr. Topper is a General Partner of Frazier Healthcare. Mr. Topper disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
January 31, 2017 Filed Jan 31, 2017 21:51 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	ConversionSeries D Preferred Stock · Derivative	733,740	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-17-006406 · doc4.xml · derivative · entry 9 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 0 Underlying: Common Stock · 733,740 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F3 · ownership.nature: Represents shares held by Frazier Healthcare VII, L.P., an affiliate of Frazier Healthcare Ventures. Dr. Topper is a General Partner of Frazier Healthcare. Mr. Topper disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
January 31, 2017 Filed Jan 31, 2017 21:51 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	ConversionSeries C-1 Preferred Stock · Derivative	195,751	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-17-006406 · doc4.xml · derivative · entry 8 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 0 Underlying: Common Stock · 195,751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F2 · ownership.nature: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Ventures. Dr. Topper is a General Partner of Frazier Healthcare. Mr. Topper disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
January 31, 2017 Filed Jan 31, 2017 21:51 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	ConversionSeries C Preferred Stock · Derivative	604,055	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-17-006406 · doc4.xml · derivative · entry 7 Topper James N · CIK 0001341382 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 0 Underlying: Common Stock · 604,055 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F2 · ownership.nature: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Ventures. Dr. Topper is a General Partner of Frazier Healthcare. Mr. Topper disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.